Longeveron Wins $1M XPRIZE Milestone, Advances to Final Phase of $101M Healthspan Competition
LGVN sits 56% above its 52-week low of $0.475.
Summary
Longeveron has been selected as one of 10 finalist teams in the XPRIZE Healthspan competition, earning a $1 million Milestone 2 award. The company will use the funds toward a future clinical trial, with a chance to compete for the $81 million grand prize. This recognition validates laromestrocel's clinical data, particularly the improved 6-minute walk distance in aging-related frailty patients. The award provides non-dilutive capital and external validation at a critical time, as the company's cash runway extends only into Q4 2026 and it faces Nasdaq delisting risk. The competition runs through 2029, offering a long-term catalyst but no immediate revenue impact.
At the time of this announcement, LGVN was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $0.48 to $1.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.